Several agents are being investigated for their effectiveness in controlling AD-related agitation; these include agonists at cannabinoid receptors (cannabidiol, dronabinol and IGC-AD1), α2 adrenergic receptors (gabapentin) and D2 receptors (brexpiprazole), and NMDA receptor antagonists, AXS-05, AVP-786 and “Smart soup”. The gene discussed is APP; the disease is Alzheimer disease.